Progressive fibrosing interstitial lung diseases (PF-ILDs) are a diverse group of ILDs that share a similar disease behavior, are characterized by a progressive disease course, and overlapping genetic, pathophysiological, and clinical features.

Join Dr. Shane Shapera for this presentation on PF-ILD.

Objectives of this webinar include:

1) Reviewing the history and rationale for “lumping” and “splitting” in Interstitial Lung Diseases (ILD);

2) Explaining the concept behind a possible role for anti-fibrotic therapy in PF-ILD;

3) Describing Scleroderma-ILD as a PF-ILD architype; and

4) Exploring the results of several recent major clinical trials looking at anti-fibrotic therapy in PF-ILD.

About The Presenter – Dr. Shane Shapera, MD, FRCPC 

Dr. Shane Shapera is an Associate Professor in the Faculty of Medicine and Division of Respirology at the University of Toronto. He is currently the Director of the Interstitial Lung Diseases Program at the Toronto General Hospital division of the University Health Network. He also works with the Toronto Lung Transplant Program providing pre-lung transplant assessments for patients with interstitial lung disease. 

This webinar is sponsored by Boehringer Ingelheim.